Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Absorbable gelatin is a sterile, water-insoluble, hemostatic agent prepared from purified porcine skin gelatin. It is primarily utilized as a medical device to control capillary, venous, and arteriolar bleeding during surgical procedures when conventional hemostasis methods like pressure or ligature are ineffective. Beyond its use as a topical hemostat (e.g., Gelfoam, Surgifoam), it is frequently processed into gelatin sponge particles (GSPs) for use as a temporary embolic agent in interventional radiology. In this capacity, it is injected intra-arterially to treat conditions such as hepatocellular carcinoma (TACE) or hypersplenism (PSE) by inducing localized ischemia. The material works through a mechanical mechanism, providing a porous matrix that promotes platelet aggregation and the formation of a physical clot, and is typically absorbed by the body within 4 to 6 weeks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on absorbable gelatin.